BIOGEN EXEC SAYS THE ALZHEIMER'S DRUG MARKET "WILL DEVELOP FASTER WITH LILLY IN PLAY", BUT CAN'T SPECULATE WHAT'S GOING TO HAPPEN WITH DONANEMAB'S LABEL